carmustine implant

**Carmustine implant** is a locally delivered, sustained-release intracranial chemotherapy product marketed as **Gliadel Wafer**. Each biodegradable polifeprosan 20 wafer contains 7.7 mg of the nitrosourea alkylating agent carmustine and is placed in the resection cavity following surgical removal of a brain tumor. The polymer matrix gradually degrades, delivering carmustine directly at the tumor site while limiting systemic exposure and bypassing the blood-brain barrier. It is FDA-approved as an adjunct to surgery and radiation for newly diagnosed high-grade glioma and as an adjunct to surgery for recurrent glioblastoma. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020637s029lbl.pdf))

Brand names

Gliadel Wafer

Other names

carmustine wafercarmustine wafer, polifeprosan 20polifeprosan 20 with carmustinepolifeprosan20 with carmustinepolifeprosan-20 with carmustinepolifeprosan 20 with carmustine implantpolifeprosan20 with carmustine implantpolifeprosan-20 with carmustine implantpolifeprosan 20, 3.85% carmustine slow-release wafer